110 related articles for article (PubMed ID: 14670325)
21. Protective efficacy of rotavirus 2/6-virus-like particles combined with CT-E29H, a detoxified cholera toxin adjuvant.
Siadat-Pajouh M; Cai L
Viral Immunol; 2001; 14(1):31-47. PubMed ID: 11270595
[TBL] [Abstract][Full Text] [Related]
22. Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis.
Mascarell L; Fayolle C; Bauche C; Ladant D; Leclerc C
J Virol; 2005 Aug; 79(15):9872-84. PubMed ID: 16014948
[TBL] [Abstract][Full Text] [Related]
23. Intranasal vaccination using interleukin-12 and cholera toxin subunit B as adjuvants to enhance mucosal and systemic immunity to human immunodeficiency virus type 1 glycoproteins.
Albu DI; Jones-Trower A; Woron AM; Stellrecht K; Broder CC; Metzger DW
J Virol; 2003 May; 77(10):5589-97. PubMed ID: 12719551
[TBL] [Abstract][Full Text] [Related]
24. Humoral immune response to rotavirus NSP4 enterotoxin in Spanish children.
Rodríguez-Díaz J; Montava R; García-Díaz A; Buesa J
J Med Virol; 2005 Oct; 77(2):317-22. PubMed ID: 16121377
[TBL] [Abstract][Full Text] [Related]
25. Cynomolgus macaques immunized with two HIV-1 Tat stabilized proteins raise strong and long-lasting immune responses with a pattern of Th1/Th2 response differing from that in mice.
Turbant S; Martinon F; Moine G; Le Grand R; Léonetti M
Vaccine; 2009 Aug; 27(39):5349-56. PubMed ID: 19607953
[TBL] [Abstract][Full Text] [Related]
26. [A fusion protein of rotavirus VP6 and cholera toxin B subunit: expression in Escherichia coli and analysis of biological activities].
Guo TX; Fang RX; Li GH; Qian Y
Sheng Wu Gong Cheng Xue Bao; 2001 Nov; 17(6):621-5. PubMed ID: 11910752
[TBL] [Abstract][Full Text] [Related]
27. Single-chain variable fragment (scFv) antibodies against rotavirus NSP4 enterotoxin generated by phage display.
Rodríguez-Díaz J; Monedero V; Pérez-Martínez G; Buesa J
J Virol Methods; 2004 Nov; 121(2):231-8. PubMed ID: 15381361
[TBL] [Abstract][Full Text] [Related]
28. Combination of cell penetrating peptides and heterologous DNA prime/protein boost strategy enhances immune responses against HIV-1 Nef antigen in BALB/c mouse model.
Kadkhodayan S; Jafarzade BS; Sadat SM; Motevalli F; Agi E; Bolhassani A
Immunol Lett; 2017 Aug; 188():38-45. PubMed ID: 28602843
[TBL] [Abstract][Full Text] [Related]
29. A synthetic HIV-1 Tat protein breaches the skin barrier and elicits Tat-neutralizing antibodies and cellular immunity.
Partidos CD; Moreau E; Chaloin O; Tunis M; Briand JP; Desgranges C; Muller S
Eur J Immunol; 2004 Dec; 34(12):3723-31. PubMed ID: 15549730
[TBL] [Abstract][Full Text] [Related]
30. Mucosal immunization with purified flagellin from Salmonella induces systemic and mucosal immune responses in C3H/HeJ mice.
Strindelius L; Filler M; Sjöholm I
Vaccine; 2004 Sep; 22(27-28):3797-808. PubMed ID: 15315861
[TBL] [Abstract][Full Text] [Related]
31. The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: implications for the design of new vaccination strategies against AIDS.
Gavioli R; Cellini S; Castaldello A; Voltan R; Gallerani E; Gagliardoni F; Fortini C; Cofano EB; Triulzi C; Cafaro A; Srivastava I; Barnett S; Caputo A; Ensoli B
Vaccine; 2008 Jan; 26(5):727-37. PubMed ID: 18096278
[TBL] [Abstract][Full Text] [Related]
32. Immunoglobulin A-deficient mice exhibit altered T helper 1-type immune responses but retain mucosal immunity to influenza virus.
Zhang Y; Pacheco S; Acuna CL; Switzer KC; Wang Y; Gilmore X; Harriman GR; Mbawuike IN
Immunology; 2002 Mar; 105(3):286-94. PubMed ID: 11918690
[TBL] [Abstract][Full Text] [Related]
33. Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant.
Borsutzky S; Ebensen T; Link C; Becker PD; Fiorelli V; Cafaro A; Ensoli B; Guzmán CA
Vaccine; 2006 Mar; 24(12):2049-56. PubMed ID: 16406225
[TBL] [Abstract][Full Text] [Related]
34. Immunogenicity of a cholera toxin B subunit Porphyromonas gingivalis fimbrial antigen fusion protein expressed in E. coli.
Kim TG; Huy NX; Kim MY; Jeong DK; Jang YS; Yang MS; Langridge WH; Lee JY
Mol Biotechnol; 2009 Feb; 41(2):157-64. PubMed ID: 18807220
[TBL] [Abstract][Full Text] [Related]
35. Cholera toxin B stimulates systemic neutralizing antibodies after intranasal co-immunization with measles virus.
Muller CP; Beauverger P; Schneider F; Jung G; Brons NH
J Gen Virol; 1995 Jun; 76 ( Pt 6)():1371-80. PubMed ID: 7782766
[TBL] [Abstract][Full Text] [Related]
36. Intranasal immunization of mice with CpG DNA induces strong systemic and mucosal responses that are influenced by other mucosal adjuvants and antigen distribution.
McCluskie MJ; Weeratna RD; Davis HL
Mol Med; 2000 Oct; 6(10):867-77. PubMed ID: 11126201
[TBL] [Abstract][Full Text] [Related]
37. Role of CD80 and CD86 in host immune responses to the recombinant hemagglutinin domain of Porphyromonas gingivalis gingipain and in the adjuvanticity of cholera toxin B and monophosphoryl lipid A.
Zhang P; Lewis JP; Michalek SM; Katz J
Vaccine; 2007 Aug; 25(33):6201-10. PubMed ID: 17629367
[TBL] [Abstract][Full Text] [Related]
38. The safety of a mucosal vaccine using the C-terminal fragment of Clostridium perfringens enterotoxin.
Suzuki H; Kakutani H; Kondoh M; Watari A; Yagi K
Pharmazie; 2010 Oct; 65(10):766-9. PubMed ID: 21105580
[TBL] [Abstract][Full Text] [Related]
39. Intranasal Immunization with Influenza Virus-Like Particles Containing Membrane-Anchored Cholera Toxin B or Ricin Toxin B Enhances Adaptive Immune Responses and Protection against an Antigenically Distinct Virus.
Ji X; Ren Z; Xu N; Meng L; Yu Z; Feng N; Sang X; Li S; Li Y; Wang T; Zhao Y; Wang H; Zheng X; Jin H; Li N; Yang S; Cao J; Liu W; Gao Y; Xia X
Viruses; 2016 Apr; 8(4):115. PubMed ID: 27110810
[TBL] [Abstract][Full Text] [Related]
40. Induction in mice of anti-Tat mucosal immunity by the intranasal and oral routes.
Le Buanec H; Vetu C; Lachgar A; Benoit MA; Gillard J; Paturance S; Aucouturier J; Gane V; Zagury D; Bizzini B
Biomed Pharmacother; 2001 Jul; 55(6):316-20. PubMed ID: 11478583
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
